NCT05794191

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Assessment of 13-valent Pneumococcal Conjugate Vaccine Effectiveness Among People With HIV in the United States

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 350,399 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream. All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13. Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.

Conditions

• HIV
• Pneumonia
• Infections, Pneumococcal

Interventions

Type	Name	Description
BIOLOGICAL	Vaccine Administration	PCV13 administration

Timeline

• Start date: 2023-03-22
• Primary completion: 2024-08-15
• Completion: 2024-08-15
• First posted: 2023-04-03
• Last updated: 2025-10-20
• Results posted: 2025-10-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study